Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026
Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025
Same author

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances·2025
Same author

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

bioRxiv : the preprint server for biology·2025
Same author

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockade.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Sep 2, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Precision medicine in AML: Function plus -omics is better than either alone.

Anthony Letai1

  • 1Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute, Cambridge, MA 02142, USA.

Cancer Cell
|August 9, 2022
PubMed
Summary
This summary is machine-generated.

This study integrates transcriptomics and ex vivo drug testing with traditional acute myelogenous leukemia (AML) diagnostics. This approach offers new insights for AML diagnosis and potential new treatments.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

239
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

9.6K

Related Experiment Videos

Last Updated: Sep 2, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

239
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

9.6K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Traditional acute myelogenous leukemia (AML) diagnostics rely on morphology, immunophenotype, cytogenetics, and genomics.
  • There is a need for novel approaches to enhance AML diagnosis and treatment strategies.

Purpose of the Study:

  • To investigate the utility of combining transcriptomics and ex vivo drug testing with established diagnostic methods in AML.
  • To identify novel diagnostic and therapeutic insights for AML patients.

Main Methods:

  • Integration of morphological, immunophenotypic, cytogenetic, and genomic data.
  • Application of transcriptomics to analyze gene expression profiles of patient myeloblasts.
  • Ex vivo drug sensitivity testing on patient-derived myeloblasts.

Main Results:

  • The combined approach yielded novel diagnostic information beyond traditional methods.
  • New therapeutic strategies were identified through ex vivo drug testing.
  • The findings suggest potential for clinical translation in AML management.

Conclusions:

  • Integrating multi-omics data and functional drug testing significantly enhances AML diagnostics.
  • This comprehensive approach holds promise for personalized medicine and improved patient outcomes in AML.